Application No.: 10/089,312 Docket No.: G0365.0355/P355

## AMENDMENTS TO THE CLAIMS

1 - 37 (canceled)

38 (currently amended). Method of [[1]] eliciting an IgA response in a mammal comprising administering orally to the mammal a composition comprising a nucleic acid operatively encoding an antigen complexed with or entrapped within liposomes formed from liposome forming components comprising

- a) at least one cationic compound
- b) zwitterionic phospholipid consisting of one or two compounds having the general formula  $\Pi$

$$O^{\circ}$$
 $|$ 
 $R^{3}COOCH_{2}CH(OCOR^{4})CH_{2}O-P-Y-R^{7}X^{2}R^{8}_{m}$ 
 $|$ 
 $O$ 

in which  $R^3$  and  $R^4$  are the same or different and are a group of the formula [[CH<sub>3</sub>(CH<sub>2</sub>)<sub>e</sub>(CH=CH-CH<sub>2</sub>)<sub>g-</sub>]] CH<sub>2</sub>(CH<sub>2</sub>)<sub>e</sub>(CH=CH-CH<sub>2</sub>)<sub>e</sub>(CH<sub>2</sub>)<sub>e</sub> in which f is 0 to 6, each of e and g + 3f are 0 to 23 and e + g is in the range 12 to 23;

R<sup>7</sup> is a C<sub>1-8</sub> alkanediyl group;

Application No.: 10/089,312 Docket No.: G0365.0355/P355

Y is -O- or a bond;

 $X^2$  is N, P or S;

m is 3 when  $X^2$  is N or P and is 2 when  $X^2$  is S; and

the groups  $R^8$  are the same or different and are selected from the group consisting of hydrogen,  $C_{1-8}$  alkyl,  $C_{6-11}$  aryl or aralkyl, or two or three of the groups  $R^8$  together with  $X^2$  form a saturated or unsaturated heterocyclic group having 5 to 7 ring atoms;

in which at least 25% by mole of the individual liposome forming components have a transition temperature of more than 40°C,

wherein the molar ratio of cationic compound to zwitterionic phospholipid is in the range 1:1 to 1:10,

whereby an IgA response to the said antigen is generated.

39 (previously presented). A method according to claim 38 in which the cationic compound has the general formula I,

$$R^{1}OCH_{2}CH(OR^{2})CH_{2}R^{5}X^{1}R^{6}$$

in which  $R^1$  and  $R^2$  are the same or different and are a group of the formula  $CH_3(CH_2)_a(CH=CH-CH_2)_b(CH_2)_c(CO)_d$  in which b is 0 to 6, a and c are each selected from 0-23 and (a + c + 3b) is in the range 12-23 and d is 0 or 1;

R<sup>5</sup> is a bond or a C<sub>1-8</sub> alkanediyl group;

 $X^1$  is N, P or S;

n is 3 where  $X^1$  is N or P and is 2 where  $X^1$  is S; and

the groups  $R^6$  are the same or different and are selected from the group consisting of hydrogen,  $C_{1-8}$  alkyl,  $C_{6-12}$  aryl and aralkyl, or two or three of the

Application No.: 10/089,312

Docket No.: G0365.0355/P355

groups  $\mathbb{R}^6$  together with  $X^1$  form a saturated or unsaturated heterocyclic group having 5 to 7 ring atoms.

40 (previously presented). A method according to claim 39 in which  $R^1$  is the same as  $R^2$  and  $R^3$  is the same as  $R^4$ .

41 (previously presented). A method according to claim 40 in which  $R^1$  and  $R^2$  represent a different group to  $R^3$  and  $R^4$ .

42 (previously presented). A method according to claim 40 in which  $R^1$  and  $R^2$  represent a different group to  $R^3$  and  $R^4$ , in which in  $R^1$  and  $R^2$ , b is 1, and in which (a+c) is in the range 10 to 20.

43 (previously presented). A method according to claim 38 in which the liposome forming materials comprise two zwitterionic phospholipids in each of which Y is O,  $X^2$  is N, and the groups  $R^8$  of the first phospholipid are all hydrogen and the groups  $R^8$  of the second phospholipid are all  $C_{1-14}$  alkyl, and  $R^7$  is  $(CH_2)_h$  in which h is 2 or 3.

44 (previously presented). A method according to claim 43 in which the groups  $\mathbb{R}^3$  and  $\mathbb{R}^4$  of the said first phospholipid are the same and each is a group in which f is 1 and (e+g) is in the range 10 to 20.

Application No.: 10/089,312

Docket No.: G0365.0355/P355

45 (previously presented). A method according to claim 44 in which in the groups R<sup>3</sup> and R<sup>4</sup> of the said second phospholipid are the same\_and each is a group in which f is 0 and e+ g is in the range 15 to 23.

46 (previously presented). A method according to claim 45 in which the said second zwitterionic phospholipid is selected from the group consisting of distearoylphosphatidylcholine, distearoylphosphatidylethanolamine, diplamitoylphosphatidylcholine and dipalmitoylphosphatidylethanolamine.

47 (previously presented). A method according to claim 38 in which the cationic compound is cholesterol-3ÿ- N-(dimethyaminoethyl) carbamate.

48 (previously presented). A method according to claim 38 in which the nucleic acid is entrapped within the liposomes.

49 (previously presented). A method according to claim 38 in which the mammal is a human.

50 (previously presented). A method according to claim 38 in which in the groups  $R^3$  and  $R^4$  of at least one phospholipid are the same.

51 (previously presented). A method according to claim 50 in which the mammal is a human.

52 (previously presented). A method according to claim 51 in which at least 50% by mole of the individual liposome forming components have a transition temperature of more than 40°C.

Application No.: 10/089,312

Docket No.: G0365.0355/P355

53 (previously presented). A method according to claim 50 in which there are two phospholipid compounds and the groups  $\mathbb{R}^3$  and  $\mathbb{R}^4$  in each phospholipid are the same.

54 (previously presented). A method according to claim 38 in which at least 50% by mole of the individual liposome forming components have a transition temperature of more than 40°C.

55 (previously presented). A method according to claim 39 in which in the groups R<sup>3</sup> and R<sup>4</sup> of at least one phospholipid are the same.

56 (previously presented). A method according to claim 55 in which the mammal is a human.

57 (previously presented). A method according to claim 55 in which there are two phospholipid compounds and the groups R<sup>3</sup> and R<sup>4</sup> in each phospholipid are the same.